Persistence of antimuscarinic drug use
Evidence suggests antimuscarinic drugs for the overactive-bladder syndrome only confer modest improvements in quality of life. We wanted to describe the persistence of therapy, including an extended analysis beyond the 1-year follow-up employed in other studies.
All prescriptions for drugs in ATC category G04BD were retrieved for the period 1999–2006 from a regional database with complete capture of all reimbursed prescriptions. Kaplan-Meyer curves were generated for duration of treatment for each substance and analyzed for determinants of termination.
With the exception of trospium chloride, all drugs had continuation rates of less than 50% at 6 months, less than 25% at 1 year, and less than 10% at 2 years and longer. Trospium chloride, however, exhibited continuation rates of 46% at 6 months, 36% at 1 year, 22% at 2 years, and 16% at 3 years.
In a setting of socialized medicine, we found higher continuation rates than previously published. Interestingly, we found that one of the older drugs on the market, trospium chloride, had a strikingly longer retention rate than other drugs.
KeywordsAdherence Antimuscarinic drugs Overactive-bladder syndrome Persistence Pharmacoepidemiology Pharmacological therapy
- 1.Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, van Kerrebroeck P, Victor A, Wein A (2002) The standardisation of terminology in lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 21:167–178PubMedCrossRefGoogle Scholar
- 4.Abrams P, Andersson KE, Buccafusco JJ, Chapple C, de Groat WC, Fryer AD, Kay G, Laties A, Nathanson NM, Pasricha PJ, Wein AJ (2006) Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder. Br J Pharmacol 148:565–578PubMedCrossRefGoogle Scholar
- 11.Shaya FT, Blume S, Gu A, Zyczynski T, Jumadilova Z (2005) Persistence with overactive bladder pharmacotherapy in a Medicaid population. Am J Managed Care 11:S121–S129Google Scholar
- 12.Chui MA (2004) Patient persistence with medication for overactive bladder. Value Health 7:366Google Scholar
- 13.Zhou Z, Barr C, Torigoe Y, Williamson T (2001) Persistence of therapy with drugs for overactive bladder. Value Health 4:161Google Scholar
- 15.Saks EK, Northington G, Gopal M, Arya L (2006) Adherence to anti-cholinergic medications in women with urge incontinence. Int Urogyn J 7:5398Google Scholar
- 19.Cox DR (1972) Regression models and life tables. J R Stat Soc B 34:187–220Google Scholar
- 21.Pesce F, Rubilotta E, D’Amico A, Siracusano S, Righetti R, Celia A, Tiberio A, Artibani W (2003) Long-term anticholinergic therapy: duration and causes of discontinuation. Abstract 304 [poster]. International Continence Society 2003, 25–27 August 2003, Paris, FranceGoogle Scholar
- 22.Brubaker L, Nichol M, Fanning K, Becker R, Jumadilova Z, Benner J (2006) Patient-reported reasons for discontinuing overactive bladder (OAB) medications. Neurourol Urodyn 25:614Google Scholar
- 23.Chapple CR, Martinez-Garcia R, Selvaggi L, Toozs-Hobson P, Warnack W, Drogendijk T, Wright DM, Bolodeoku J (2005) A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol 48:464–470PubMedGoogle Scholar
- 24.Boccuzzi SJ, Le TK, Wogen J, Williamson T (2002) Utilization patterns associated with tolterodine immediate release versus oxybutinin in the management of urinary incontinence (UI). Value Health 5:274Google Scholar